The video states that the drugs are currently in stage two clinical trials with humans. The presenters predict FDA approval sometime between 2027 and 2028.
The video only names Regeneron Pharmaceuticals as the company conducting the trials discussed. It mentions that other pharmaceutical companies are working on similar treatments, but doesn't name them.
This video discusses a new class of muscle-building drugs, non-androgenic anabolics, developed by Regeneron Pharmaceuticals. The speakers analyze a study on these drugs using non-human primates, highlighting their potential to surpass steroids in muscle growth while minimizing side effects.
Based on the video, the presenters suggest that the primary side effect of the new muscle-building drugs might be increased hunger and a need for higher protein intake due to the radical increase in muscle mass. They mention that this could be mitigated by using a weight-loss drug like semaglutide to offset the increased appetite. The primate study showed minimal other side effects, unlike the significant androgenic side effects associated with steroids. The presenters explicitly state that the drugs, as studied, exhibited "zero androgenic side effects."